Variability in the antibody clones, expression thresholds, scoring systems and the cell types expressing PD-L1 among FDA/EMA-approved PD-L1 assays across multiple cancer types can pose difficulty of interpretation for researchers and clinicians. This evidence concerns the gene CD274 and cancer.